The anti-IL-6R antibodies tocilizumab and sarilumab and the anti-IL-6 antibody siltuximab are currently being tested in 13 clinical trials for efficacy in managing COVID-19 CSS and pneumonia [55]. This evidence concerns the gene IL6 and pneumonia.